Transaction

ThirdWay Capital's Investment in Fluorobiotech Biotech's Operations in South Africa

Announced
12 March 2026
Target
Fluorobiotech (Pty) Ltd
Value
Undisclosed
Asset class
Venture Capital
Type
Investment
Instrument
Equity
Lead investors
ThirdWay Capital
Investors
ThirdWay Capital
Sector
Healthcare / Biotechnology, Pharmaceuticals
Markets
South Africa

About the target

Fluorobiotech (Pty) Ltd is a South Africa-based biotechnology company specialising in the local production of high-value enzymes and recombinant proteins. Founded in 2022 and headquartered at the LaunchLab CERI BIO laboratories in Stellenbosch, South Africa, the company produces molecular enzymes for In Vitro Transcription (IVT) workflows, mRNA vaccine manufacturing, diagnostics, and biological research. Fluorobiotech principal clients include biopharma innovators, vaccine developers, and academic and industrial research institutions. A spin-out of Stellenbosch University, Fluorobiotech is incubated through the Innovus Technology Transfer Office and LaunchLab. The company's patented SelfPrep technology enables scalable, high-yield enzyme manufacturing at reduced production costs, and is available both as a product and under licensing arrangements. Fluorobiotech holds ISO 13485 certification, awarded in December 2025.

Sources

  1. www.linkedin.com
  2. Partner Researchers